Priority Review in Merkel Cell Carcinoma, Breakthrough Designation in RET-Altered Cancers, and More

Gina Columbus reports on a priority review designation in Merkel cell carcinoma, a breakthrough therapy designation in select RET-altered cancers, an application submitted in pediatric ALL, and European approvals in multiple myeloma, melanoma, and ALL.

• categorie